Pharmacy Drugs
Recent Posts
- Novelos Therapeutics’ (NVLT.OB) CEO Is Eyeing “Revolutionary” Phase III Study Results
- Investigational Dual Orexin Receptor Antagonist Almorexant Meets Primary Endpoint In Two-week Phase III Study Of Primary Insomnia
- PHT Corporation’s Market Leading LogPad And StudyWorksTM EPRO Solutions Used In Sanofi Pasteur’s Phase II Study Of New Clostridium Difficile Vaccine
- Small Molecules Found To Protect Cells In Multiple Models Of Parkinson’s Disease
- Arena Pharmaceuticals Announces Merck Discontinues Development Of Investigational Niacin Receptor Agonist Program For Atherosclerosis
Random Posts
- Arizona Heart Institute Enrolls First Patient In Anaconda(TM) Investigational Study For The Treatment Of Abdominal Aortic Aneurysm
- National Survey: Parents Report Increased Awareness Of Risks Of Teen Prescription Drug Abuse, But Preventative Action Lags
- Néovacs To Expand Clinical Testing Of Its TNF-alpha Kinoid Lead Product Candidate Following Positive Preliminary Findings From A Phase I/II Study
- Teach Your Patients About Their Medicines To Avoid Misadventure, UK
- Prereg Tutor Training Day And Prereg Trainee Pharmacist Programme 2009/10 - Booking Now
- Hard To Treat Diseases (HTDS) Clinical Trial Update On Therapeutic Effects Of Combined Treatment With Ribavirin And Tiazofurin
- FDA Likely to Approve H1N1 Vaccine In Advance of Data
- GSK's HPV Cervical Cancer Vaccine Shows Superior Immune Response To Competitor Vaccine In First Head-to-head Study
- PAION AG: Phase Ib And IIa Studies Of The Anesthetic/Sedative CNS 7056 On Track
- First Swine Flu Vaccine Trials Begin in Australia
FDA Accepts Arno Therapeutics’ IND For AR-12 A PDK1 Inhibitor That Blocks The PI3K/Akt Pathway
Posted by: admin in Pharmacy Drugs on November 23rd, 2009
Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on oncology therapeutics, announced that the U.S.
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.